Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal cord FDG PET uptake in healthy adults: an AI-driven segmentation study.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

DaRenCa risk score: A prognostic model for recurrence in clear cell renal cell carcinoma.

BJUI compass·2026
Same author

[Late sequelae after major urological surgery].

Ugeskrift for laeger·2026
Same author

Quantification of Costal Cartilage Calcification Using <sup>18</sup>F-NaF-PET/CT.

Journal of imaging·2026
Same author

<sup>18</sup>F-NaF and <sup>18</sup>F-FDG PET/CT imaging of spinal instrumentation: case report and review of the literature.

American journal of nuclear medicine and molecular imaging·2026
Same author

Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

European urology·2026
Same journal

<sup>18</sup>F-fluorodeoxyglucose PET in Major Psychiatric Disorders.

PET clinics·2026
Same journal

Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.

PET clinics·2026
Same journal

FDG PET in Movement Disorders and Parkinsonian Syndromes.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Encephalitis and Postinfectious Neurocognitive Syndromes.

PET clinics·2026
Same journal

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

PET clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

FDG in Urologic Malignancies.

Poul Flemming Høilund-Carlsen1, Mads Hvid Poulsen2, Henrik Petersen3

  • 1Department of Nuclear Medicine, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark; Institute of Clinical Research, University of Southern Denmark, Winsløwparken 19, DK-5000, Odense, Denmark.

PET Clinics
|June 9, 2015
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) and computed tomography (CT) imaging are crucial for diagnosing kidney, bladder, and prostate cancers. While FDG-PET/CT may show false negatives, this could indicate slow-growing cancers needing no immediate therapy.

Keywords:
Bladder cancerFDGProstate cancerRadionuclide imagingRenal cancer

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.4K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.7K

Related Experiment Videos

Last Updated: Apr 11, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.4K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.7K

Area of Science:

  • Urologic oncology
  • Medical imaging
  • Nuclear medicine

Background:

  • Kidney, bladder, and prostate cancers represent a significant global health burden.
  • Computed tomography (CT) is the primary imaging modality for kidney cancer.
  • Positron emission tomography (PET) imaging for bladder cancer faces challenges due to urinary excretion of 18F-fluoro-deoxy-glucose (FDG).

Purpose of the Study:

  • To evaluate the role and interpretation of PET/CT imaging in urologic cancers.
  • To address the perceived high rate of false-negative results with FDG-PET/CT in urologic malignancies.

Main Methods:

  • Review of current imaging practices in kidney, bladder, and prostate cancer.
  • Analysis of the application and limitations of FDG-PET/CT in urologic oncology.
  • Discussion of the implications of FDG-PET/CT findings in relation to cancer behavior.

Main Results:

  • CT remains dominant for kidney cancer imaging.
  • FDG-PET/CT application is more frequent in prostate cancer.
  • Urinary excretion of FDG hinders bladder cancer PET imaging.
  • Reported false-negative FDG-PET/CT results in urologic cancers may reflect indolent disease.

Conclusions:

  • The interpretation of FDG-PET/CT findings in urologic cancers requires careful consideration of tumor biology.
  • False-negative results might indicate slow-growing cancers with favorable prognoses, potentially avoiding overtreatment.
  • Further research into optimized PET tracers and imaging protocols for urologic cancers is warranted.